“We are thrilled to partner with MIMEDX to bring RegenKit®-Wound Gel to patients across the United States, » said Franck Maingonnat, VP of Business Development at Regen Lab.
This collaboration underscores our commitment to advancing regenerative medicine and providing clinicians with innovative, autologous solutions that improve outcomes for patients with wounds. MIMEDX’s expertise and national reach make them an ideal partner to expand access to this clinically proven therapy“.
Regen Lab Global is pleased to share an important milestone for our U.S. presence: RegenLab USA has announced an exclusive agreement with MiMedx for the distribution of RegenKit®-Wound Gel in the United States.
This collaboration expands access to a fully autologous solution designed to support healthcare professionals in the management of chronic wounds, and complements MiMedx’s advanced wound care portfolio with an additional differentiated option.
A fully autologous solution supporting chronic wound care
RegenKit®-Wound Gel is a fully autologous solution prepared from the patient’s own blood, with the objective of providing a standardized and reproducible approach for clinical use within appropriate medical practice and local regulations.
The solution is supported by multiple published studies evaluating its effectiveness in chronic wound management.
A shared commitment to quality, evidence, and clinical practice
At Regen Lab Global, we are committed to developing and supporting solutions grounded in:
-
Quality and standardization in preparation processes
-
Clinical relevance for real-world practice
-
Scientific evidence through published research
-
Education and training to support healthcare teams
This agreement reflects a shared ambition with MiMedx: to bring high-quality, evidence-backed options to clinicians working in advanced wound care.